European journal of haematology

· 6 papers in corpus
case-report 2026
doi:10.1111/ejh.70163 ·PMID:41846581

Background and aimsRetroperitoneal Infantile Fibrosarcoma (RIFS) is a rare, locally aggressive pediatric soft tissue tumor. Its retroperitoneal location poses challenges due to proximity and potential invasion of critical structures such as…

case-report 2002
doi:10.1034/j.1600-0609.2002.01669.x ·PMID:12071939

Danazol has been used with success in some hematological diseases, but there is no report of this treatment in acute leukemia. We report here a case of remission of myelodysplastic syndrome with myelofibrosis in transformation after danazol…

other 1991
doi:10.1111/j.1600-0609.1991.tb01555.x ·PMID:1915803

We examined the effects of danazol on in vitro growth of human bone marrow and peripheral blood progenitor cells from 15 normal donors and 5 myelodysplastic patients, and on in vivo hemopoiesis in 30 patients with hypoplastic or myelodyspla…

review 1990
doi:10.1111/j.1600-0609.1990.tb00341.x ·PMID:2407548

Pernicious anemia appears to be autoimmune in origin and is associated with immune disorders of several organ systems. We report 4 patients with pernicious anemia and immune cytopenias, an association that may sometimes pose diagnostic prob…

other 1990
doi:10.1111/j.1600-0609.1990.tb00427.x ·PMID:2209813
nonrandomized-trial 1987
doi:10.1111/j.1600-0609.1987.tb00780.x ·PMID:3319676

20 patients with myelodysplastic syndromes (MDS) were treated with danazol, 800 mg daily in 4 divided doses. 18 patients were evaluable for response. 3 patients (17%), whose principal problem was anemia, responded to treatment, but only wit…